Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 65 Results

Title
Intervention Indication Therapeutic Area Year Actions
Rivoceranib for locally advanced or metastatic gastric or gastro-oesophageal junction cancer - after two or more therapies Rivoceranib (Apatinib; YN968D1) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2020 View  |  Download
Ripretinib for treating advanced gastrointestinal stromal tumours – fourth-line Ripretinib (DCC-2618; Quinlock) Gastrointestinal stromal tumour (GIST) Gastrointestinal Cancer 2020 View  |  Download
Ripretinib for gastrointestinal stromal tumour Ripretinib (DCC-2618; Quinlock) Gastrointestinal stromal tumour (GIST) Gastrointestinal Cancer 2021 View  |  Download
Retifanlimab for squamous carcinoma of the anal canal – after platinum based chemotherapy Retifanlimab (INCMGA00012; MGA-012) Anal cancer Gastrointestinal Cancer 2020 View  |  Download
Ramucirumab for Advanced Hepatocellular Carcinoma – second line Ramucirumab (Cyramza) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2018 View  |  Download
Ramucirumab (Cyramza) + capecitabine or 5-FU + cisplatin for gastric cancer of GOJ – treatment naive for palliative chemotherapy 5-Fluorouracil , Capecitabine (Xeloda) , Cisplatin (Platinol) , Ramucirumab (Cyramza) Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Pexastimogene devacirepvec (pexa-vec) for hepatocellular carcinoma – first line Pexastimogene devacirepvec (Pexa-vec; JX-594) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Pemigatinib for locally advanced or metastatic, relapsed or refractory cholangiocarcinoma with FGFR2 fusion or rearrangement Pemigatinib (INCB054828) Cholangiocarcinoma Gastrointestinal Cancer 2019 View  |  Download
Pembrolizumab with Lenvatinib and chemotherapy for previously untreated advanced or metastatic gastroesophageal adenocarcinoma Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Gastroesophageal adenocarcinoma Gastrointestinal Cancer 2023 View  |  Download
Pembrolizumab plus chemotherapy for the treatment of gastric cancer or gastro-oesophageal junction cancer – First Line Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications